Work

Abstract 2281: AZD4241, an orally bioavailable ERα PROTAC, degrades wild-type and mutant ERα and delivers anti-tumour activity in preclinical breast cancer models

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-2281

Authors: Mandy Lawson, Natalie Cureton, Lynet Nyoni, Sophie D’Arcy, Lydia Parkinson, Ana Quiroga, Pablo Morentin Gutierrez, Ji Li, Hana Baakza, Thomas Hayhow, Claire Crafter, Lucy Ireland, Gemma Hardman Fowler, Georgia M. Simmons, Lakjaya Buluwela, Simak Ali, Neil Gibson

Institutions: AstraZeneca (United Kingdom), Imperial College London

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7148847789

Cites:

Cited by:

Related to: